TRANSAMINASES AND THE INFLUENCE OF SILYMARIN IN EPIRUBICIN CHEMOTHERAPY REGIMENS IN MICE
(Abstract release date: 05/21/15)
EHA Library. Alciona S. 06/12/15; 103010; PB1948
Disclosure(s): Vasile Goldis Western University of AradHematology
Sasu Alciona
Contributions
Contributions
Abstract
Abstract: PB1948
Type: Publication Only
Background
Epirubicin is a chemotherapeutic drug used in the haematological malignancies regimens. Epirubicin forms a complex with DNA, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is extensively and rapidly metabolized by the liver, one of the reported toxicities being the hepatotoxicity. Serum aminotransferase elevations occur in up to 40% of patients on antraciclin therapy. There are some natural compounds that have been investigated for their hepatoprotective effects.
Aims
The scope of this study was to evaluate the hepatotoxicity of epirubicin as seen through the elevation of transaminases and in parallel to evaluate the protective effect of silymarin in mice treated with epirubicin and silymarin.
Methods
The study included 6 mice experimental lots (first lot with no treatment, the second lot treated with epirubicin alone, the third and the forth lots treated with epirubicin and silymarin 50 and 100mg/day, the fifth and sixth lots treated with silymarin alone, 50 and 100mg/day).
Results
The results showed that in the epirubicin treated lot, the level of ASAT was increased compared to the lots treated with epirubicine and silymarine or silymarine alone (p=0,0111 for the lot treated with epirubicin and also 50mg silymarine/day, p= 0.0374 for the ot treated with epirubicin and also with 100mg silymarine/day). Concerning the ALAT, we haven’t found any statistical significant results in the compared lots.
Summary
As a conclusion, silymarine could have a hepatic protective effect when taken in the same time with the epirubicin included regimens in mice.
Session topic: Publication Only
Type: Publication Only
Background
Epirubicin is a chemotherapeutic drug used in the haematological malignancies regimens. Epirubicin forms a complex with DNA, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is extensively and rapidly metabolized by the liver, one of the reported toxicities being the hepatotoxicity. Serum aminotransferase elevations occur in up to 40% of patients on antraciclin therapy. There are some natural compounds that have been investigated for their hepatoprotective effects.
Aims
The scope of this study was to evaluate the hepatotoxicity of epirubicin as seen through the elevation of transaminases and in parallel to evaluate the protective effect of silymarin in mice treated with epirubicin and silymarin.
Methods
The study included 6 mice experimental lots (first lot with no treatment, the second lot treated with epirubicin alone, the third and the forth lots treated with epirubicin and silymarin 50 and 100mg/day, the fifth and sixth lots treated with silymarin alone, 50 and 100mg/day).
Results
The results showed that in the epirubicin treated lot, the level of ASAT was increased compared to the lots treated with epirubicine and silymarine or silymarine alone (p=0,0111 for the lot treated with epirubicin and also 50mg silymarine/day, p= 0.0374 for the ot treated with epirubicin and also with 100mg silymarine/day). Concerning the ALAT, we haven’t found any statistical significant results in the compared lots.
Summary
As a conclusion, silymarine could have a hepatic protective effect when taken in the same time with the epirubicin included regimens in mice.
Session topic: Publication Only
Abstract: PB1948
Type: Publication Only
Background
Epirubicin is a chemotherapeutic drug used in the haematological malignancies regimens. Epirubicin forms a complex with DNA, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is extensively and rapidly metabolized by the liver, one of the reported toxicities being the hepatotoxicity. Serum aminotransferase elevations occur in up to 40% of patients on antraciclin therapy. There are some natural compounds that have been investigated for their hepatoprotective effects.
Aims
The scope of this study was to evaluate the hepatotoxicity of epirubicin as seen through the elevation of transaminases and in parallel to evaluate the protective effect of silymarin in mice treated with epirubicin and silymarin.
Methods
The study included 6 mice experimental lots (first lot with no treatment, the second lot treated with epirubicin alone, the third and the forth lots treated with epirubicin and silymarin 50 and 100mg/day, the fifth and sixth lots treated with silymarin alone, 50 and 100mg/day).
Results
The results showed that in the epirubicin treated lot, the level of ASAT was increased compared to the lots treated with epirubicine and silymarine or silymarine alone (p=0,0111 for the lot treated with epirubicin and also 50mg silymarine/day, p= 0.0374 for the ot treated with epirubicin and also with 100mg silymarine/day). Concerning the ALAT, we haven’t found any statistical significant results in the compared lots.
Summary
As a conclusion, silymarine could have a hepatic protective effect when taken in the same time with the epirubicin included regimens in mice.
Session topic: Publication Only
Type: Publication Only
Background
Epirubicin is a chemotherapeutic drug used in the haematological malignancies regimens. Epirubicin forms a complex with DNA, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is extensively and rapidly metabolized by the liver, one of the reported toxicities being the hepatotoxicity. Serum aminotransferase elevations occur in up to 40% of patients on antraciclin therapy. There are some natural compounds that have been investigated for their hepatoprotective effects.
Aims
The scope of this study was to evaluate the hepatotoxicity of epirubicin as seen through the elevation of transaminases and in parallel to evaluate the protective effect of silymarin in mice treated with epirubicin and silymarin.
Methods
The study included 6 mice experimental lots (first lot with no treatment, the second lot treated with epirubicin alone, the third and the forth lots treated with epirubicin and silymarin 50 and 100mg/day, the fifth and sixth lots treated with silymarin alone, 50 and 100mg/day).
Results
The results showed that in the epirubicin treated lot, the level of ASAT was increased compared to the lots treated with epirubicine and silymarine or silymarine alone (p=0,0111 for the lot treated with epirubicin and also 50mg silymarine/day, p= 0.0374 for the ot treated with epirubicin and also with 100mg silymarine/day). Concerning the ALAT, we haven’t found any statistical significant results in the compared lots.
Summary
As a conclusion, silymarine could have a hepatic protective effect when taken in the same time with the epirubicin included regimens in mice.
Session topic: Publication Only
{{ help_message }}
{{filter}}